Abstract: A ferrocenyl compound having the general formula (I): (I) Het is a substituted or unsubstituted heterocyclic moiety. L1, L2 and L3 are each a linker independently selected from alkylene, alkyleneoxy, alkyleneoxyalkylene, alkylenecarbonyl, alkyleneoxycarbonyl, alkyleneamido, alkyleneoxyamido, alkenylene, alkenyleneoxy, alkenylenecarbonyl, alkenyleneamido, alkynylene, alkynyleneoxy, alkynylenecarbonyl and alkynyleneamido, all of which may be straight chain or branched, substituted or unsubstituted. R1 and R2 are each independently selected from H, substituted or unsubstituted alkyl carbonyl, substituted or unsubstituted aryl carbonyl, substituted or unsubstituted phosphate, substituted or unsubstituted phosphonate and substituted or unsubstituted phosphoramidate. M and n are each 0 or 1 and m+n?0.1.

Abstract: A radio- or chemo-sensitizing compound is described herein. The compound comprises a nanoparticle and attached to the nanoparticle; (i) a DNA repair inhibitor; and (ii) a nuclear localization signal element (NLS); each optionally attached via one or more linker moieties.

Abstract: A method of generating surface geometry information of an object within an imaged region using an imaging system comprising a camera and a source of structured light, the source of structured light comprising a source of a plurality of rays of light. The method comprising obtaining first image data comprising a plurality of pixels, the first image data comprising image data representing the object and first structured light incident on the object, the first structured light comprising a periodic pattern comprising a plurality of pattern elements and having a first spatial frequency projected from said source of structured light and obtaining second image data comprising a plurality of pixels, the second image data comprising image data representing the object and providing information associating each of the plurality of image pixels of the second image data with a ray of said source of structured light.

Abstract: ?-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of ?-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising ?-mannosylceramide, as well as methods of treatment of tumors are also provided.

Abstract: Biologically acceptable composition for the prophylaxis and/or treatment of colorectal cancer. The composition contains an iron chelator, and the composition is adapted for the selective targeting of the iron chelator to the colon. The iron chelator is non-digestible, non-absorbable and non-fermentable in the gastrointestinal tract.

Abstract: ?-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of ?-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising ?-mannosylceramide, as well as methods of treatment of tumors are also provided.

Abstract: ?-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of ?-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising ?-mannosylceramide, as well as methods of treatment of tumors are also provided.

Abstract: The protein NM23 is disclosed as an agent for the maintenance of undifferentiated biological cells in culture. The NM23 protein may act as a survival factor for such cultured cells, or to prevent the differentiation and maturation of the cultured cells. The use of NM23 protein is applicable to culture of stem and/or progenitor cells, and particularly to such cells cultured and adapted for therapeutic use. The invention provides methods, media and media supplements for use in the culture of biological cells, and further provides methods of preparing biological cells for therapeutic use, as well as methods of therapy utilising biological cells and medicaments comprising biological cells adapted for therapeutic use.